Biosig Technologies (BSGM) Raised to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Biosig Technologies (OTCMKTS:BSGM) from a hold rating to a buy rating in a research note issued to investors on Friday morning. The firm currently has $1.50 price objective on the stock.

According to Zacks, “BioSig Technologies, Inc. is a medical device company which is engaged in developing technology platform to improve cardiac recording during electrophysiology studies and ablation procedures. “

Separately, Chardan Capital reiterated a buy rating on shares of Biosig Technologies in a research note on Sunday, October 1st.

Biosig Technologies (BSGM) opened at $1.39 on Friday. Biosig Technologies has a one year low of $1.20 and a one year high of $2.00.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at

Biosig Technologies Company Profile

BioSig Technologies, Inc is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System.

Get a free copy of the Zacks research report on Biosig Technologies (BSGM)

For more information about research offerings from Zacks Investment Research, visit

What are top analysts saying about Biosig Technologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Biosig Technologies Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit